Apeiron Closes $17.5 Million Series A and Launches Strategic Partnerships

GT Apeiron Therapeutics (‘Apeiron’) announced it has completed a $17.5 million Series A financing. Panacea Venture led the investment round with participation from Viva BioInnovator and existing investors. This is the company’s second round of financing in the last year following a Pre-A+ round in May 2021. The investment will enable the company to advance […]

Apeiron is making its debut at AACR

Dr. Fred Aswad, SVP of Biology at Apeiron will present preclinical data on GTAEXS617, a novel, orally bioavailable, selective small-molecule inhibitor of CDK7 discovered using AI-driven drug discovery. GTAEXS617 is currently in IND-enabling studies. Preclinical data demonstrates that GTAEXS617 has favorable drug like properties and exhibits potent anti-tumour activity in HGSOC and TNBC xenograft tumour-bearing […]

Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture

Combines Exscientia’s leading AI-driven drug identification and design capabilities with GT Apeiron’s expertise in cyclin-dependent kinase (CDK) targets for oncology Expands existing CDK7 drug discovery partnership with additional CDK targeting drugs    Oxford & Shanghai – July 21st, 2021 – Exscientia, an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and […]

GT Apeiron Therapeutics Strengthens Advisory Board

Keith Lenden and Dr. Honggang Bi has been appointed as new members of the Advisory Board at GT Apeiron Therapeutics, an AI empowered drug discovery start-up developing oncology therapeutics. Mr. Lenden and Dr. Bi add further expertise in drug discovery innovation, translational medicine, and clinical development; and deep knowledge and perspectives from both USA and Asia-Pacific region, to the Company’s Advisory Board. Mr. Keith […]

Apeiron Therapeutics opens US headquarter

Apeiron Therapeutics opens US headquarter in the San Francisco Bay Area. The Bay Area office will enable Apeiron to tap into the deep expertise and talent pool at the intersection of biotechnology and artificial intelligence in the Bay Area and in the broader US. Fred Aswad, Ph.D., J.D., and Vice President of Biology will lead […]

GT Healthcare has launched GT Apeiron, an AI-driven drug development company in Shanghai

GT Healthcare Capital Partners (“GT Healthcare”), a life science-focused private equity partnership which specializes in capital investments and market scalability in Asia/ Greater China region, has launched an AI-driven drug development company in SHANGHAI, June 1, 2019— GT Apeiron Therapeutics (“Apeiron Therapeutics”) SHANGHAI, June 1st, 2019 GT Healthcare Capital Partners (“GT Healthcare”)has launched an AI-driven […]

Apeiron Therapeutics

Apeiron Therapeutics was launched in 2019 by GT Healthcare Capital Partners. It is a Shanghai-headquartered biotechnology platform utilizing state-of-the-art technologies for drug discovery. About Healthcare Capital Partners GT Healthcare Capital Partners is an Asia-based private equity firm that specializes in life science investments around the globe that aim to benefit patients. GT Healthcare aims to […]